Cost-consequence analysis of remifentanil-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands

Maiwenn J Al, Leona Hakkaart, Siok Swan Tan, Jan Bakker, Maiwenn J Al, Leona Hakkaart, Siok Swan Tan, Jan Bakker

Abstract

Introduction: Hospitals are increasingly forced to consider the economics of technology use. We estimated the incremental cost-consequences of remifentanil-based analgo-sedation (RS) vs. conventional analgesia and sedation (CS) in patients requiring mechanical ventilation (MV) in the intensive care unit (ICU), using a modelling approach.

Methods: A Markov model was developed to describe patient flow in the ICU. The hourly probabilities to move from one state to another were derived from UltiSAFE, a Dutch clinical study involving ICU patients with an expected MV-time of two to three days requiring analgesia and sedation. Study medication was either: CS (morphine or fentanyl combined with propofol, midazolam or lorazepam) or: RS (remifentanil, combined with propofol when required). Study drug costs were derived from the trial, whereas all other ICU costs were estimated separately in a Dutch micro-costing study. All costs were measured from the hospital perspective (price level of 2006). Patients were followed in the model for 28 days. We also studied the sub-population where weaning had started within 72 hours.

Results: The average total 28-day costs were €15,626 with RS versus €17,100 with CS, meaning a difference in costs of €1474 (95% CI -2163, 5110). The average length-of-stay (LOS) in the ICU was 7.6 days in the RS group versus 8.5 days in the CS group (difference 1.0, 95% CI -0.7, 2.6), while the average MV time was 5.0 days for RS versus 6.0 days for CS. Similar differences were found in the subgroup analysis.

Conclusions: Compared to CS, RS significantly decreases the overall costs in the ICU.

Trial registration: Clinicaltrials.gov NCT00158873.

Figures

Figure 1
Figure 1
Model outline.
Figure 2
Figure 2
Hourly transition probabilities from the 'Mechanical ventilation - maintenance' state.
Figure 3
Figure 3
Hourly transition probabilities from the 'Mechanical Ventilation - weaning started' state.
Figure 4
Figure 4
Hourly transition probabilities from the 'Post-extubation' state.
Figure 5
Figure 5
Hourly transition probabilities from the 'eligible for ...' state (state 2 to 3, state 4 to 5, and state 6 to 7).

References

    1. Gravel NR, Searle NR, Sahab PG, Carrier M. Sedation in critically ill patients: practical recommendations. CNS Drugs. 1999;11:9–22. doi: 10.2165/00023210-199911010-00002.
    1. Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79:881–892. doi: 10.1097/00000542-199311000-00004.
    1. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C, Tasker R. Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury. Intensive Care Med. 2006;32:380–390. doi: 10.1007/s00134-005-0060-y.
    1. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, De Backer D, Dobb G, Fagon JY, Gerlach H, Groeneveld J, Macrae D, Mancebo J, Metnitz P, Nava S, Pugin J, Pinsky M, Radermacher P, Richard C. Year in review in Intensive Care Medicine, 2006. II. Infections and sepsis, haemodynamics, elderly, invasive and noninvasive mechanical ventilation, weaning, ARDS. Intensive Care Med. 2007;33:214–229. doi: 10.1007/s00134-006-0512-z.
    1. Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med. 2001;163:540–577.
    1. Battershill AJ, Keating GM. Remifentanil: a review of its analgesic and sedative use in the intensive care unit. Drugs. 2006;66:365–385. doi: 10.2165/00003495-200666030-00013.
    1. James MK, Feldman PL, Schuster SV, Bilotta JM, Brackeen MF, Leighton HJ. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. J Pharmacol Exp Ther. 1991;259:712–718.
    1. Kapila A, Glass PS, Jacobs JR, Muir KT, Hermann DJ, Shiraishi M, Howell S, Smith RL. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83:968–975. doi: 10.1097/00000542-199511000-00009.
    1. Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology. 1993;79:893–903. doi: 10.1097/00000542-199311000-00005.
    1. Gusmao Vicente F, Polito Lomar F, Melot C, Vincent JL. Can the experienced ICU physician predict ICU length of stay and outcome better than less experienced colleagues? Intensive Care Med. 2004;30:655–659. doi: 10.1007/s00134-003-2139-7.
    1. Rozendaal FW, Spronk PE, Snellen FF, Schoen A, van Zanten AR, Foudraine NA, Mulder PG, Bakker J. Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands. Intensive Care Med. 2009;35:291–298. doi: 10.1007/s00134-008-1328-9.
    1. GlaxoSmithKline: Fachinformation Ultiva.
    1. Tan SS, Hakkaart-van Roijen L, Al MJ, Bouwmans CA, Hoogendoorn ME, Spronk PE, Bakker J. A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med. 2008;23:250–257. doi: 10.1177/0885066608318661.
    1. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
    1. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18:341–364. doi: 10.1016/S0167-6296(98)00039-3.
    1. NICE: Guide to the Methods of Technology Appraisal.
    1. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178. doi: 10.1586/14737167.8.2.165.
    1. Muellejans B, Matthey T, Scholpp J, Schill M. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial [abstract] Crit Care. 2006;10:R91. doi: 10.1186/cc4939.
    1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903.
    1. Langer M, Mosconi P, Cigada M, Mandelli M. Long-term respiratory support and risk of pneumonia in critically ill patients. Intensive Care Unit Group of Infection Control. Am Rev Respir Dis. 1989;140:302–305.
    1. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, Jaeschke RZ, Brun-Buisson C. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998;129:433–440.
    1. Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol. 2004;25:1090–1096. doi: 10.1086/502349.
    1. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122:2115–2121. doi: 10.1378/chest.122.6.2115.
    1. Nseir S, Hoel J, Grailles G, Soury-Lavergne A, Di Pompeo C, Mathieu D, Durocher A. Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study. Crit Care. 2009;13:R60. doi: 10.1186/cc7788.
    1. Feng P, Wilson QM, Meissler JJ Jr, Adler MW, Eisenstein TK. Increased sensitivity to Salmonella enterica serovar Typhimurium infection in mice undergoing withdrawal from morphine is associated with suppression of interleukin-12. Infect Immun. 2005;73:7953–7959. doi: 10.1128/IAI.73.12.7953-7959.2005.
    1. Feng P, Truant AL, Meissler JJ Jr, Gaughan JP, Adler MW, Eisenstein TK. Morphine withdrawal lowers host defense to enteric bacteria: spontaneous sepsis and increased sensitivity to oral Salmonella enterica serovar Typhimurium infection. Infect Immun. 2006;74:5221–5226. doi: 10.1128/IAI.00208-06.
    1. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998;26:676–684. doi: 10.1097/00003246-199804000-00015.
    1. Delvaux B, Ryckwaert Y, Van Boven M, De Kock M, Capdevila X. Remifentanil in the intensive care unit: tolerance and acute withdrawal syndrome after prolonged sedation. Anesthesiology. 2005;102:1281–1282. doi: 10.1097/00000542-200506000-00030.
    1. Muellejans B, Lopez A, Cross MH, Bonome C, Morrison L, Kirkham AJ. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial (ISRCTN43755713) Crit Care. 2004;8:R1–R11. doi: 10.1186/cc2398.
    1. Breen D, Karabinis A, Malbrain M, Morais R, Albrecht S, Jarnvig IL, Parkinson P, Kirkham AJ. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial (ISRCTN47583497) Crit Care. 2005;9:R200–210. doi: 10.1186/cc3495.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi